NeonMind is a psychedelic drug development company. It's mission is to help people change their lives by changing their minds, through treatment with psychedelics.
NeonMind’s initial focus is on finding a potential treatment for obesity with psilocybin dosing. It has hired the University of British Columbia, which has been granted authorization by Health Canada to use Psilocybin in NeonMind’s Preclinical Trial, to test the potential use of psilocybin to improve eating habits and cause weight loss. The Preclinical Trial started in November 2020 and NeonMind expects to complete an application for a Phase 2 Human Trial in the spring of 2021.
NeonMind has filed 5 US provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual by administering psilocybin and/or other psychedelic compounds or their analogs or by administering psilocybin or its analog in conjunction with therapy or other treatments. For more information on NeonMind, go to www.NeonMindBiosciences.com
NeonMind is also pursuing commercialization of its catalogue of proprietary medicinal mushroom product formulas. It recently launched a collection of four mushroom infused coffees which are infused with medicinal mushrooms Lion's Mane, Turkey Tail, Reishi and Cordyceps. The NeonMind eCommerce platform launched in November 2020 at www.neonmind.com
for direct to consumer sales of these products.
- Ms. Penny White – Founder, President & Chief Exec. Officer
- Mr. Rick Huang – Chief Financial Officer
- Mr. Trevor Millar – Chief Psychedelic Officer
- Dr. William Panenka – Chair, Scientific Advisory Board
- Ms. Amber Allen – Vice President, Sales